07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

AGEN1884: Phase I started

Agenus began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate AGEN1884 in about 48 patients. The company gained the product through its 2014 acquisition of 4-Antibody AG. Agenus Inc. (NASDAQ:AGEN), Lexington, Mass....
08:00 , Jan 9, 2015 |  BC Extra  |  Company News

One year later, Agenus hits home run with Incyte deal

Shares of Agenus Inc. (NASDAQ:AGEN) jumped $1.18 (29%) to $5.30 on Friday, adding $82.6 million in market cap, after the company entered a five-year collaboration with Incyte Corp. (NASDAQ:INCY) to develop and commercialize novel immuno-therapeutics...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Agenus, Merck deal

Agenus will use its 4-Antibody Retrocyte Display antibody platform to discover human antibodies against two undisclosed immune checkpoint targets from Merck to treat cancer. Agenus will be responsible for discovery and optimization, and Merck will...
07:00 , Mar 31, 2014 |  BioCentury  |  Finance

LSP's steady hand

When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months - early stage, European drug development companies....
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Agenus, Ludwig Cancer Research deal

The partners selected three antibody checkpoint modulators to advance into preclinical development for cancer, including two agonists of glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18) and a CTLA-4 (CD152) antagonist....
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Agenus, 4-Antibody deal

Agenus completed the acquisition of antibody company 4-Antibody for 3.3 million shares, which is valued at about $10.1 million based on Agenus' closing price of $3.03 on Feb. 12, before the close of the deal....
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Agenus, 4-Antibody deal

Agenus will acquire antibody company 4-Antibody for $10 million up front in Agenus stock plus additional contingent payments, payable in cash or stock, that may exceed $40 million. Agenus will gain 4-Antibody's antibody discovery technology...
07:00 , Jun 10, 2013 |  BioCentury  |  Product Development

Post-Yervoy Landscape

Four key presentations at last week's American Society of Clinical Oncology meeting spotlighted the pace at which the next wave of cancer immunotherapies are building a case to supplant Yervoy ipilimumab. Immune checkpoint inhibitors from Bristol-Myers...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

4-Antibody, Recepta Biopharma, Ludwig Institute for Cancer Research deal

4-Antibody and the institute expanded a May 2011 deal to include Recepta as a development partner as well as three additional undisclosed targets with roles in the suppression of immune responses in cancer patients. In...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

4-Antibody, GlaxoSmithKline deal

4-Antibody received two undisclosed milestone payments from Human Genome Sciences Inc. under an August 2011 deal to use 4-Antibody's Retrocyte Display in vitro library screening technology to discover and develop human antibodies against two...